Welcome to Business Insider‘s daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.
Hello,
The coronavirus pandemic is overwhelming the US yet again, with the country recording its 2 worst-ever days of infection over the weekend.
“We are not going to control the pandemic,” White House Chief of Staff Mark Meadows said Sunday on CNN.
Also in healthcare news: Gilead’s set to make billions on a drug that’s far from “amazing”, AstraZeneca and Johnson & Johnson have restarted vaccine trials in the US, and universal masking could save 130,000.
Vials of the drug Remdesivir pictured during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany on April 8, 2020, amidst the new coronavirus COVID-19 pandemic.
ULRICH PERREY/POOL/AFP via Getty Images
ULRICH PERREY/POOL/AFP via Getty Images
Gilead is set to sell billions of dollars of a coronavirus drug that's far from 'amazing' after the US approved remdesivir to treat COVID-19
- Gilead Sciences is poised to sell billions of dollars worth of the first COVID-19 treatment approved by US regulators, despite mixed evidence on whether or not the drug actually works.
- A trial conducted earlier this year found hospitalized COVID-19 patients taking remdesivir recovered modestly faster than those on getting a placebo. The study did not find that the drug reduced deaths in a statistically meaningful way.
- Despite the uncertainty on its efficacy, Wall Street analysts expect the drug to bring in more than $4 billion in revenue over 2020 and 2021.
Read the full story from Andrew Dunn here>>
Capped vials are being pictured during filling and packaging tests for the large-scale production and supply of the University of Oxfords COVID-19 vaccine candidate, AZD1222
VINCENZO PINTO/AFP via Getty Images
VINCENZO PINTO/AFP via Getty Images
AstraZeneca and Johnson & Johnson get FDA green light to resume coronavirus vaccine trials in the US after participants got sick
- Two major coronavirus vaccine trials — one by AstraZeneca and the University of Oxford, the other by Johnson & Johnson — will resume coronavirus vaccine trials in the US, the companies announced Friday.
- AstraZeneca's late-stage trial had paused September 6 after the company reported "suspected serious adverse reaction" in a UK-based participant.
- Johnson & Johnson halted trials on October 12 after a participant developed an unexplained illness.
- The UK resumed clinical trials for AstraZeneca and the University of Oxford vaccines in September, and in Japan earlier this month.
Read the full story from Allana Akhtar here>>
AP Photo/Alex Brandon
Universal mask-wearing could save 130,000 US lives before March, mitigating the worst of this 3rd coronavirus surge
- The US's total coronavirus deaths could surpass 511,000 by the end of February, according to a new University of Washington model.
- Nearly 130,000 of those lives could be saved if 95% of the country wore masks, the model found.
- Mask-wearing, the researchers wrote, could delay the need for lockdowns and mitigate the worst of the fall-winter surge.
Read the full story from Aria Bendix here>>
More stories we're reading:
- WATCH: Horseshoe crab blood could help scientists create a coronavirus vaccine. Here's why the liquid is so expensive. (Business Insider)
- An inside look at the FDA's efforts to push back at Trump's rush to a vaccine (Vanity Fair)
- Blood plasma didn't show benefit in COVID-19 patients, according to a new study (Stat News)
- Merck scientists wanted to get started on vaccine in February, but were overruled by senior execs (The Wall Street Journal)
Subscribe here for daily updates from the healthcare team!
- Lydia